Patents by Inventor Nicolas Willand
Nicolas Willand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11253499Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by Mycobacterium, such as tuberculosis.Type: GrantFiled: August 15, 2018Date of Patent: February 22, 2022Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, BIOVERSYS AGInventors: Esther Porras De Francisco, Modesto Jesús Remuiñan-Blanco, Marilyne Bourotte, Benoit Deprez, Geoffroy Dequirez, Nicolas Willand
-
Patent number: 11254689Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.Type: GrantFiled: August 15, 2018Date of Patent: February 22, 2022Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, BIOVERSYS AGInventors: Esther Porras De Francisco, Modesto Jesús Remuiñan-Blanco, Marilyne Bourotte, Benoit Deprez, Nicolas Willand
-
Publication number: 20210032268Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.Type: ApplicationFiled: August 15, 2018Publication date: February 4, 2021Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, BIOVERSYS AGInventors: Esther PORRAS DE FRANCISCO, Modesto Jesús REMUIÑAN-BLANCO, Marilyne BOUROTTE, Benoit DEPREZ, Nicolas WILLAND
-
Publication number: 20200253967Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.Type: ApplicationFiled: August 15, 2018Publication date: August 13, 2020Inventors: Esther PORRAS DE FRANCISCO, Modesto Jesús REMUIÑAN-BLANCO, Marilyne BOUROTTE, Benoit DEPREZ, Nicolas WILLAND
-
Publication number: 20200170997Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.Type: ApplicationFiled: August 15, 2018Publication date: June 4, 2020Inventors: Esther PORRAS DE FRANCISCO, Modesto Jesús REMUIÑAN-BLANCO, Marilyne BOUROTTE, Benoit DEPREZ, Geoffroy DEQUIREZ, Nicolas WILLAND
-
Patent number: 10174050Abstract: The present invention concerns a spiroisoxazoline compound of general formula (I): in which m and n are 0 or 1, R1 represents, inter alia, an optionally substituted alkyl chain, in particular substituted with fluorine or with a cyclic group, and R2 is chosen from phenyl and optionally substituted benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the heterocycles having 5 or 6 vertices comprising at least one atom chosen from S, N and O. The present invention also concerns the use of this compound as a drug, in particular in the treatment of bacterial and mycobacterial infections such as tuberculosis in combination with an antibiotic that is active against bacteria and/or mycobacteria, said compound potentiating the activity of said antibiotic.Type: GrantFiled: December 20, 2013Date of Patent: January 8, 2019Assignee: Universite de Droit et de la Sante de Lille 2Inventors: Nicolas Willand, Benoit Deprez, Alain Baulard, Priscille Brodin, Matthieu Frederik Desroses, Laurence Agouridas-Dutot
-
Patent number: 9957249Abstract: The present invention concerns a compound of general formula (I): in which n=0 or 1, R1 represents an optionally substituted alkyl chain, in particular substituted alkyl chain, in particular substituted with fluorine, X is chosen from N and CH, and R2 is chosen from optionally substituted phenyl and benzyl, wherein the heterocycles having 6 vertices comprise one, two or three nitrogen atoms. The present invention also concerns the use of this compound as a medicament, in particular in the treatment of bacterial and mycobacterial infections such as tuberculosis in combination with an antibiotic that is active against bacteria and/or mycobacteria, said compound potentiating the activity of said antibiotic.Type: GrantFiled: December 20, 2013Date of Patent: May 1, 2018Assignee: UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2Inventors: Nicolas Willand, Benoit Deprez, Alain Baulard, Priscille Brodin, Marion Flipo, Lucie Maingot
-
Patent number: 9920042Abstract: The present invention concerns compounds of general formula (I): in which Y and Z are chosen from CH and N; T is chosen from CO or SO2; n is 1 to 3; R1 represents a group chosen, for example, from C1-C3 alkyl chains unsubstituted or substituted by fluorine, the unsubstituted or substituted cyclic, cyano, azido, alkoxy and phenyl groups; and R is chosen from the azido, cyano, alkinyl and 2-benzothiazolyl groups and an optionally substituted aromatic heterocycle with five vertices; and the use thereof in the treatment of bacterial and mycobacterial infections such as, for example, tuberculosis, leprosy and atypical mycobacterial infections. The present invention also concerns pharmaceutical compositions comprising, as the active ingredient, at least one of the abovementioned compounds and optionally an antibiotic activatable via the EthA pathway.Type: GrantFiled: September 27, 2013Date of Patent: March 20, 2018Assignee: UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2Inventors: Nicolas Willand, Benoit Deprez, Alain Baulard, Priscille Brodin, Olivier Sperando, Vincent Villeret, Baptiste Villemagne
-
Publication number: 20150344498Abstract: The present invention concerns a spiroisoxazoline compound of general formula (I): in which m and n are 0 or 1, R1 represents, inter alia, an optionally substituted alkyl chain, in particular substituted with fluorine or with a cyclic group, and R2 is chosen from phenyl and optionally substituted benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the heterocycles having 5 or 6 vertices comprising at least one atom chosen from S, N and O. The present invention also concerns the use of this compound as a drug, in particular in the treatment of bacterial and mycobacterial infections such as tuberculosis in combination with an antibiotic that is active against bacteria and/or mycobacteria, said compound potentiating the activity of said antibiotic.Type: ApplicationFiled: December 20, 2013Publication date: December 3, 2015Applicant: Universite de Droit et de la Sante de Lille 2Inventors: Nicolas Willand, Benoit Deprez, Alain Baulard, Priscille Brodin, Matthieu Frederik Desroses, Laurence Agouridas-Dutot
-
Publication number: 20150307471Abstract: The present invention concerns a compound of general formula (I): in which n=0 or 1, R1 represents an optionally substituted alkyl chain, in particular substituted alkyl chain, in particular substituted with fluorine, X is chosen from N and CH, and R2 is chosen from optionally substituted phenyl and benzyl, wherein the heterocycles having 6 vertices comprise one, two or three nitrogen atoms. The present invention also concerns the use of this compound as a medicament, in particular in the treatment of bacterial and mycobacterial infections such as tuberculosis in combination with an antibiotic that is active against bacteria and/or mycobacteria, said compound potentiating the activity of said antibiotic.Type: ApplicationFiled: December 20, 2013Publication date: October 29, 2015Applicant: Universite de Droit et de la Sante de Lille 2Inventors: Nicolas Willand, Benoit Deprez, Alain Baulard, Priscille BRODIN, Marion FLIPO
-
Publication number: 20150225388Abstract: The present invention concerns compounds of general formula (I): in which Y and Z are chosen from CH and N; T is chosen from CO or SO2; n is 1 to 3; R1 represents a group chosen, for example, from C1-C3 alkyl chains unsubstituted or substituted by fluorine, the unsubstituted or substituted cyclic, cyano, azido, alkoxy and phenyl groups; and R is chosen from the azido, cyano, alkinyl and 2-benzothiazolyl groups and an optionally substituted aromatic heterocycle with five vertices; and the use thereof in the treatment of bacterial and mycobacterial infections such as, for example, tuberculosis, leprosy and atypical mycobacterial infections.Type: ApplicationFiled: September 27, 2013Publication date: August 13, 2015Inventors: Nicolas Willand, Benoit Deprez, Alain Baulard, Priscille Brodin, Olivier Sperando, Vincent Villeret, Baptiste Villemagne
-
Patent number: 8962658Abstract: The present invention relates to compounds of Formula (I) wherein R1 is chosen among the following radicals: and n=1 or 2 and m=1 or 2 with the proviso that m=2 when R1 is The present invention also relates to the use thereof as drugs, more particularly in the treatment of mycobacterial infections and more particularly in the treatment of tuberculosis.Type: GrantFiled: October 24, 2012Date of Patent: February 24, 2015Assignee: Universite de Droit et de la Sante de Lille 2Inventors: Benoit Deprez, Nicolas Willand, Marion Flipo, Matthieu Desroses, Alain Baulard, Florence Leroux
-
Publication number: 20140309238Abstract: The present invention relates to compounds of Formula (I), wherein R1 is chosen among the following radicals: (II); (III); (IV), (V), (VI) (VII) and n=1 or 2 and m=1 or 2 with the proviso that m=2 when R1 is (VIII). The present invention also relates to the use thereof as drugs, more particularly in the treatment of mycobacterial infections and more particularly in the treatment of tuberculosis.Type: ApplicationFiled: October 24, 2012Publication date: October 16, 2014Applicants: Universite de Droit et de la Sante de Lille 2, INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Pasteur de LilleInventors: Benoit Deprez, Nicolas Willand, Marion Flipo, Matthieu Desroses, Alain Baulard, Florence Leroux
-
Patent number: 8338599Abstract: The present invention relates to the use of compounds with a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, for the preparation of a medicament for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy, to pharmaceutical compositions comprising them in combination with an antibiotic that is activatable via the EthA pathway, to compounds having a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, to pharmaceutical compositions comprising them and to their use as medicaments, especially medicaments for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy.Type: GrantFiled: July 4, 2007Date of Patent: December 25, 2012Assignees: Institut Pasteur de Lille, Centre National de la Recherche Scientifique, Universite de Lille 2, Universite du Droit et de la Sante, Institut National de la Sante et de la Recherche Medicale (Inserm)Inventors: Benoît Deprez, Nicolas Willand, Bertrand Dirie, Patrick Toto, Vincent Villeret, Camille Locht, Alain Baulard
-
Publication number: 20110136823Abstract: The present invention relates to the use of compounds with a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, for the preparation of a medicament for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy, to pharmaceutical compositions comprising them in combination with an antibiotic that is activatable via the EthA pathway, to compounds having a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, to pharmaceutical compositions comprising them and to their use as medicaments, especially medicaments for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy.Type: ApplicationFiled: July 4, 2007Publication date: June 9, 2011Applicants: Institut Pasteur De Lille, Centre National De La Recherche Scientifique, Universite De Lille 2, Universite Du Droit Et De La Sante, Institut National De La Sante Et De La Recherche Medicale (Inserm)Inventors: Benôit Deprez, Nicolas Willand, Dirie Bertrand, Toto Patrick, Villeret Vincent, Locht Camille, Baulard Alain